Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Jennifer Friedmann, Michelino De Laurentiis et al.|Journal of Clinical Oncology|2024Cited by 163
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast CancerSara A. Hurvitz, Amanda Gillespie-Twardy, Rachel M. Layman et al.|Journal of Clinical Oncology|2026Cited by 4